Switch theme
Sign up to access all valuation multiples
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
2007
13
LTM Revenue $0.2M
LTM EBITDA -$3.4M
$5.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Spago Nanomedical has a last 12-month revenue (LTM) of $0.2M and a last 12-month EBITDA of -$3.4M.
In the most recent fiscal year, Spago Nanomedical achieved revenue of $0.2M and an EBITDA of -$3.4M.
Spago Nanomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Spago Nanomedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $0.2M | XXX | -$1.3M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -647% | XXX | XXX | XXX |
| EBITDA | -$3.4M | XXX | -$3.4M | XXX | XXX | XXX |
| EBITDA Margin | -1650% | XXX | -1730% | XXX | XXX | XXX |
| EBIT | -$3.5M | XXX | -$3.4M | XXX | XXX | XXX |
| EBIT Margin | -1700% | XXX | -1747% | XXX | XXX | XXX |
| Net Profit | -$3.4M | XXX | -$3.4M | XXX | XXX | XXX |
| Net Margin | -1650% | XXX | -1701% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Spago Nanomedical's stock price is SEK 0 (or $0).
Spago Nanomedical has current market cap of SEK 78.3M (or $8.1M), and EV of SEK 51.8M (or $5.3M).
See Spago Nanomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.3M | $8.1M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Spago Nanomedical has market cap of $8.1M and EV of $5.3M.
Spago Nanomedical's trades at 27.1x EV/Revenue multiple, and -1.6x EV/EBITDA.
Equity research analysts estimate Spago Nanomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spago Nanomedical has a P/E ratio of -2.4x.
See valuation multiples for Spago Nanomedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.1M | XXX | $8.1M | XXX | XXX | XXX |
| EV (current) | $5.3M | XXX | $5.3M | XXX | XXX | XXX |
| EV/Revenue | 25.9x | XXX | 27.1x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/EBIT | -1.5x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 25.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.4x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | -1.6x | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSpago Nanomedical's revenue per employee in the last FY averaged $15K, while opex per employee averaged $0.2M for the same period.
Spago Nanomedical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Spago Nanomedical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Spago Nanomedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1650% | XXX | -1730% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $15K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1100% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spago Nanomedical acquired XXX companies to date.
Last acquisition by Spago Nanomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Spago Nanomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Spago Nanomedical founded? | Spago Nanomedical was founded in 2007. |
| Where is Spago Nanomedical headquartered? | Spago Nanomedical is headquartered in Sweden. |
| How many employees does Spago Nanomedical have? | As of today, Spago Nanomedical has 13 employees. |
| Is Spago Nanomedical publicy listed? | Yes, Spago Nanomedical is a public company listed on STO. |
| What is the stock symbol of Spago Nanomedical? | Spago Nanomedical trades under SPAGO ticker. |
| When did Spago Nanomedical go public? | Spago Nanomedical went public in 2012. |
| Who are competitors of Spago Nanomedical? | Similar companies to Spago Nanomedical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Spago Nanomedical? | Spago Nanomedical's current market cap is $8.1M |
| What is the current revenue of Spago Nanomedical? | Spago Nanomedical's last 12 months revenue is $0.2M. |
| What is the current EV/Revenue multiple of Spago Nanomedical? | Current revenue multiple of Spago Nanomedical is 25.9x. |
| Is Spago Nanomedical profitable? | Yes, Spago Nanomedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Spago Nanomedical? | Spago Nanomedical's last 12 months EBITDA is -$3.4M. |
| What is Spago Nanomedical's EBITDA margin? | Spago Nanomedical's last 12 months EBITDA margin is -1650%. |
| What is the current EV/EBITDA multiple of Spago Nanomedical? | Current EBITDA multiple of Spago Nanomedical is -1.6x. |
| What is the current FCF of Spago Nanomedical? | Spago Nanomedical's last 12 months FCF is -$3.4M. |
| What is Spago Nanomedical's FCF margin? | Spago Nanomedical's last 12 months FCF margin is -1650%. |
| What is the current EV/FCF multiple of Spago Nanomedical? | Current FCF multiple of Spago Nanomedical is -1.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
